As of 2025-07-19, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is (20.20) USD. This relative valuation is based on P/E multiples. With the latest stock price at 16.76 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -220.5%.
The range of the Relative Valuation is (15.74) - (25.33) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 24.3x | 19.6x |
| Forward P/E multiples | 13.1x - 24.8x | 19.2x |
| Fair Price | (15.74) - (25.33) | (20.20) |
| Upside | -193.9% - -251.1% | -220.5% |
| Date | P/E |
| 2025-07-18 | -16.08 |
| 2025-07-17 | -18.08 |
| 2025-07-16 | -17.55 |
| 2025-07-15 | -16.91 |
| 2025-07-14 | -17.85 |
| 2025-07-11 | -17.56 |
| 2025-07-10 | -18.09 |
| 2025-07-09 | -18.11 |
| 2025-07-08 | -16.82 |
| 2025-07-07 | -16.15 |
| 2025-07-03 | -16.11 |
| 2025-07-02 | -16.21 |
| 2025-07-01 | -15.43 |
| 2025-06-30 | -15.16 |
| 2025-06-27 | -15.42 |
| 2025-06-26 | -15.41 |
| 2025-06-25 | -15.02 |
| 2025-06-24 | -15.31 |
| 2025-06-23 | -14.88 |
| 2025-06-20 | -14.70 |
| 2025-06-18 | -14.98 |
| 2025-06-17 | -14.87 |
| 2025-06-16 | -15.06 |
| 2025-06-13 | -15.10 |
| 2025-06-12 | -15.56 |
| 2025-06-11 | -16.06 |
| 2025-06-10 | -16.28 |
| 2025-06-09 | -15.89 |
| 2025-06-06 | -16.12 |
| 2025-06-05 | -15.79 |
| 2025-06-04 | -16.06 |
| 2025-06-03 | -15.93 |
| 2025-06-02 | -15.73 |
| 2025-05-30 | -15.41 |
| 2025-05-29 | -16.13 |
| 2025-05-28 | -14.93 |
| 2025-05-27 | -14.74 |
| 2025-05-23 | -14.51 |
| 2025-05-22 | -14.76 |
| 2025-05-21 | -14.69 |
| 2025-05-20 | -15.63 |
| 2025-05-19 | -15.10 |
| 2025-05-16 | -15.07 |
| 2025-05-15 | -14.71 |
| 2025-05-14 | -14.30 |
| 2025-05-13 | -14.66 |
| 2025-05-12 | -13.40 |
| 2025-05-09 | -12.50 |
| 2025-05-08 | -12.71 |
| 2025-05-07 | -12.53 |